TYLER, Texas — Medical technology company NanoVibronix, Inc. has announced the pricing of a $10 million underwritten public offering, which includes approximately 400,000 shares of its Series G Convertible Preferred Stock and accompanying warrants to purchase up to 4.9 million shares of common stock.
Each unit, consisting of one share of preferred stock and an accompanying warrant, is priced at $25.00. The warrants will allow investors to purchase common stock at an exercise price of $2.04 per share. The offering is expected to close on or about May 19, 2025, pending customary closing conditions.
Dawson James Securities, Inc. is serving as the sole bookrunning manager for the offering.
NanoVibronix, which specializes in non-invasive therapeutic ultrasound devices, anticipates using the net proceeds from the offering to redeem a $1.3 million outstanding debenture issued in February 2025 and to repay up to $700,000 of an additional note issued in January 2025. Remaining funds will be allocated toward general corporate purposes.
The public offering is being conducted under a registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission. A final prospectus will be filed and made available through the SEC’s website and from Dawson James Securities.
The company emphasized that the announcement does not constitute an offer to sell or a solicitation to buy, and that the sale of the securities will only occur in compliance with applicable securities laws.
